Ascendis Pharma Oncology Division A/S: Financial statements 2023
CVR: 41034076
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
Ascendis Pharma Oncology Division A/S (CVR 41034076) has filed annual accounts for 2023. In 2023, the company reported a gross profit of EUR -140,146,399 and a net result of EUR -144,110,203 compared with EUR -64,912,248 the year before. Equity in the 2023 report amounted to EUR -285,131,102.
- Gross Profit
- EUR -140,146,399
- Profit/Loss
- EUR -144,110,203
- Equity
- EUR -285,131,102
- Total Assets
- EUR 456,642
- Employees
- 0
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | - | -140.1M EUR | -144.1M EUR | -285.1M EUR | 0 |
| 2022 | - | -62.4M EUR | -64.9M EUR | -141M EUR | 0 |
| 2021 | - | -46.7M EUR | -48M EUR | -76.1M EUR | 0 |
| 2020 | - | -35.7M EUR | -36.1M EUR | -28.1M EUR | 0 |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record, straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
Ascendis Pharma Oncology Division A/S has published its annual report for 2022. Gross profit came to DKK -62,367,388, and the net result was DKK -64,912,248.
About Ascendis Pharma Oncology Division A/S
Ascendis Pharma Oncology Division A/S is a Danish company of the type Aktieselskab based in Hellerup, founded in 2019. The company is registered under the industry Fremstilling af farmaceutiske præparater. The management consists of Jan Møller Mikkelsen. The board consists of Michael Wolff Jensen (chair), Anni Lotte Kirstine Pedersen and Jan Møller Mikkelsen. The company is owned by ASCENDIS PHARMA A/S. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of EUR -85,226,000 and a net result of EUR -110,131,000 compared with EUR -106,375,000 the year before. Equity in the 2025 report amounted to EUR -501,637,000.
